About this trial
The purpose of this study is to evaluate the blood pressure-lowering effect of tonlamarsen in adult participants who were recently hospitalized and concurrently experienced an episode of acute severe hypertension.
Eligibility criteria
Qualifiers
Age 18 or older, body weight ≥ 50 kg with BMI ≤45.0 kg/m2
Ready for discharge or recently discharged from the hospital to home (within the past 7 days) during which evaluation and/or treatment of acute severe hypertension (documented SBP ≥ 180 mmHg and/or DBP ≥ 110 mmHg) occurred, as measured by a healthcare provider (HCP) within the 24 hours preceding hospitalization or during the initial 24 hours of hospitalization
At Screening and Randomization visit, average resting office systolic blood pressure ≥ 145 mmHg
Presence of established cardiovascular or renal disease
Disqualifiers
Has known history of secondary hypertension
Any malignancy requiring treatment within 5 years (except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated)
Has abnormal thyroid function with clinical significance
Recent hospitalization for stroke, myocardial infarction or coronary revascularization within 30 days prior to screening
Trial design
Treatments tested in this trial
- Tonlamarsen
- Placebo